Winning Health Technology Group (300253) Fundamentals 2026 — Revenue Analysis | SniperIQ
Winning Health Technology Group (300253) is a CN-listed Healthcare company in Medical - Healthcare Information Services with a market capitalization of ¥15.1B, trading at ¥6.88 on the SHZ. This SniperIQ fundamentals page covers Winning Health Technology Group's valuation, profitability (net margin -16.9%), revenue (¥2.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Winning Health Technology Group's market cap?
Winning Health Technology Group (300253) has a market capitalization of approximately ¥15.1B, trading at ¥6.88 on the SHZ. Market cap moves with the live share price.
What is Winning Health Technology Group's P/E ratio?
Winning Health Technology Group's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Winning Health Technology Group?
Winning Health Technology Group runs a net profit margin of -16.9%, a gross margin of 32.2%, and an operating margin of -20.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Winning Health Technology Group generate?
Winning Health Technology Group reported revenue of ¥2.1B for fiscal year 2025, with net income of -¥374M and earnings per share (EPS) of -0.17. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Winning Health Technology Group pay a dividend?
Winning Health Technology Group does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Winning Health Technology Group financially healthy?
Winning Health Technology Group carries a debt-to-equity ratio of 0.21x and a current ratio of 3.13x, with a market beta of 0.48. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Winning Health Technology Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Winning Health Technology Group (300253) the key facts are: market cap ¥15.1B, revenue ¥2.1B, 52-week range 6.47-16.09. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Winning Health Technology Group's full fundamentals live
Get Winning Health Technology Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.